Sun Pharma arm launches breast cancer drug Palbociclib in India

Mumbai: Sun Pharmaceutical Industries Limited toay announced that one of its wholly-owned subsidiaries has launched a novel anti-cancer drug, Palbociclib in India for patients who have advanced breast cancer, the most common cancer among women in the country.

The company will make the drug available under the brand name, PALENO (Palbociclib) 75 mg, 100 mg, 125 mg

Kirti Ganorkar, CEO – India Business, Sun Pharma, said "We are introducing Palbociclib at an affordable price which will help improve patient access. PALENO will address the treatment need of several advanced breast cancer patients in India. For the first time, we are introducing a unique patient assistance program that will improve patient compliance and accessibility."

Read also: Sun Pharma gets CDSCO panel nod to manufacture, market Esomeprazole dual release gastroresistant tablets

Palbociclib is approved by the USFDA, EMA and CDSCO in combination with hormonal therapies for patients with hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer.

Breast cancer is the largest form of cancer in India, affecting approximately 0.21 million new female patients every year. Among the total patients, approximately 50% are hormone receptor positive breast cancer, the major subtype in breast cancer. Though hormone receptor positive breast cancer patients have shown better survival than other subtypes, they may progress to or present with metastatic disease.  

Read also: Sun Pharma, SPARC collaborate for commercialization of phenobarbital for injection in US      

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates.

Read also: Sun Pharma's proposal to amend CT protocol for pimavanserin gets CDSCO Panel nod